SCHEMBL4825636

SCHEMBL4825636

CCN1C(=O)C(C)(C)c2cc3[nH]c(-c4n[nH]cc4NC(=O)c4ccc(C)s4)nc3cc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.52
AURKB Q96GD4 2/20 0.52
CHEK1 O14757 1/20 0.36
SRC P12931 1/20 0.36
CDK2 P24941 1/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
GSK3B P49841 1/20 0.36
ALDH1A1 P00352 6/20 0.34
SMN1; SMN2 Q16637 5/20 0.34
HPGD P15428 4/20 0.34
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
TP53 P04637 2/20 0.33
LMNA P02545 2/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826410 0.88 AURKA (0.50) AURKAAURKBALDH1A1SMN1; SMN2HPGD
SCHEMBL4829059 0.86 AURKA (0.53) AURKAAURKBCHEK1SRCCDK2
SCHEMBL4829418 0.85 AURKA (0.58) AURKAAURKBCHEK1SRCCDK2
SCHEMBL4823345 0.85 AURKA (0.52) AURKAAURKBCHEK1SRCCDK2
SCHEMBL4829193 0.85 AURKA (0.58) AURKAAURKBCHEK1SRCCDK2
SCHEMBL4830762 0.85 AURKA (0.52) AURKAAURKBCHEK1SRCCDK2
SCHEMBL4829102 0.84 AURKA (0.57) AURKAAURKBCHEK1SRCCDK2
SCHEMBL4823342 0.84 AURKA (0.57) AURKAAURKBCHEK1SRCCDK2
SCHEMBL4830704 0.84 AURKA (0.51) AURKAAURKBCHEK1SRCCDK2
SCHEMBL4826491 0.84 AURKA (0.63) AURKAAURKBCHEK1SRCCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060235065-A1 Aminopyrazole derivatives HOFFMANN-LA ROCHE INC. 2006-10-19 US claimed
US-7462639-B2 e.g 3-(7,7-Dimethyl-6-oxo-1,5,6,7-tetrahydro-imidazo[4,5-f]indol-2-yl)-1H-pyrazol-4-yl]-carbamic acid benzyl ester; Aurora A (serotonin/threonine) kinase inhibitors; anticarcinogenic agent; colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian cancer, melanoma, neuroblastoma HOFFMANN-LA ROCHE INC. (US) 2008-12-09 US disclosed
US-20060235065-A1 Aminopyrazole derivatives HOFFMANN-LA ROCHE INC. 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235065-A1 Aminopyrazole derivatives CYP3A43, CYP3A5, CYP3A4 AURKA 742/4885AURKB 1096/4885CHEK1 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.